Michael Magliochetti, Ph.D.
Mike has more than 30 years of private equity and operations experience. He joined RS2 Healthcare Partners as an Operating Partner in 2012.
Prior to RS2 Healthcare Partners, Mike served as CEO of Claros Diagnostics, a point-of-care in-vitro diagnostic firm, which was honored as one of the Top 50 Most Innovative Companies in the World for 2011 by MIT Technology Review, and acquired by OPKO Health. Prior to Claros, he served as CEO of RMH, a leading orthopedic products company, and as CEO of both HemaMetrics and UroSurge. Mike previously held senior positions with Haemonetics and Delta Surprenant, and completed an assignment with the U.S. Army Research Command.
In addition to serving on the Board of Overseers for Boston Museum of Science, Advisory Boards for Boston Children’s Hospital, Lahey Clinic and Medical Development Group-Boston, Mike has also served as an Adjunct Professor of Biomedical Engineering at the University of Iowa and consulted with several medical device and pharmaceutical companies.
Education
Mike holds a Bachelor of Science degree in Chemical Engineering and a Master of Business Administration from Northeastern University, and a Ph.D. in Chemical Engineering from the University of Massachusetts at Amherst.